Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Disc Medicine (IRON – Research Report) and Boston Scientific (BSX – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Disc Medicine (IRON)
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Disc Medicine today and set a price target of $110.00. The company’s shares closed last Thursday at $71.30.
According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of
Disc Medicine has an analyst consensus of Strong Buy, with a price target consensus of $121.10, implying a 67.1% upside from current levels. In a report issued on January 8, Morgan Stanley also maintained a Buy rating on the stock with a $120.00 price target.
See the top stocks recommended by analysts >>
Boston Scientific (BSX)
In a report released today, Michael Matson from Needham maintained a Buy rating on Boston Scientific, with a price target of $121.00. The company’s shares closed last Thursday at $90.15.
According to TipRanks.com, Matson is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $126.12 average price target, which is a 42.9% upside from current levels. In a report issued on January 5, Bank of America Securities also maintained a Buy rating on the stock with a $120.00 price target.
